How to Launch a Profitable TRT/HRT Telehealth Practice

Market Opportunity: Men's TRT and Women's HRT

The U.S. hormone optimization market is one of the fastest-growing segments in specialty telehealth, driven by increasing patient awareness, declining stigma around hormonal health, and the structural advantages of telehealth over in-person endocrinology and urology practices. The men's TRT market and the women's HRT market are distinct in their clinical pathways but are often served by the same practice infrastructure, making hormone optimization one of the highest-leverage specialties for a telehealth founder. Before committing to a technology stack, review what to look for in TRT telehealth software in 2026 — the platform decision is among the highest-leverage choices you will make in the first 60 days.

Men's TRT Market

Testosterone deficiency affects an estimated 10–40% of adult men depending on the diagnostic threshold applied, with prevalence increasing significantly in men over 40. The traditional care pathway — referral to endocrinology or urology, insurance preauthorization, in-office injections — is slow, expensive, and inconvenient. Telehealth TRT clinics have disrupted this pathway by offering online consultations, at-home lab testing, and direct-to-patient pharmacy fulfillment in a membership model that costs $150–$300 per month all-in.

The resulting consumer behavior shift is structural, not cyclical. Patients who have experienced the convenience of telehealth TRT rarely return to the traditional system. Retention rates for TRT memberships are exceptional compared to other telehealth categories: 3–5% monthly churn versus 8–15% for general telehealth subscriptions. The clinical rationale is straightforward — stopping TRT requires a deliberate decision, and the benefits of treatment are tangible and measurable.

Women's HRT Market

The women's HRT market is experiencing a resurgence driven by the reversal of the Women's Health Initiative's early conclusions about hormone therapy safety, growing menopause awareness, and a cohort of millennial women who are proactively managing perimenopause and menopause. Women's HRT protocols — estradiol (patch, gel, pellet, or oral), progesterone, testosterone (off-label for libido and energy), and DHEA — require a different clinical workflow than men's TRT but are highly compatible with the same telehealth practice infrastructure.

The women's HRT market adds significant average revenue per patient when layered onto a men's TRT practice. Women's HRT patients often pursue more comprehensive hormonal optimization including thyroid support, adrenal support, and nutritional supplementation, creating upsell and ancillary revenue opportunities that are less common in the typical men's TRT membership.

Business Model Options

Before executing on any operational detail, you must select the business model that matches your goals, capital position, and clinical resources. The three primary models — solo DTC, group practice, and franchise/licensing — differ substantially in their startup requirements, revenue ceilings, and operational complexity.

Solo Direct-to-Consumer Model

The solo DTC model is the fastest to launch and most common entry point for physician founders. A single licensed physician or a supervised NP/PA operates under a PC, sees all patients, and manages the practice with minimal administrative support in the early stages. The economics are highly favorable: with a lean technology stack and compounding pharmacy partnerships, a solo provider can reach $15,000–$25,000 in monthly recurring revenue at 80–150 active patients with overhead below $8,000 per month, yielding EBITDA margins of 40–55%.

The constraint is capacity. A full-time provider managing TRT patients — each requiring quarterly consultations plus lab review touchpoints — typically maxes out at 300–400 active patients before wait times degrade conversion rates and patient satisfaction. The solo model is appropriate for years one and two; the transition to a group model should be planned before the capacity constraint is hit, not after.

Group Practice Model

A group practice operates multiple providers under a shared PC and centralized operational infrastructure. Revenue scales with headcount — each NP or PA typically carries 200–350 active patients — while fixed costs (technology, compliance, administration) are shared. Group practices benefit from protocol standardization, cross-coverage during provider absences, and the ability to offer extended hours without a single provider burning out.

The startup cost for a group practice model is higher: you need an MSO/PC structure with management services agreements, provider contracts, a more sophisticated EHR with multi-provider workflows, and HR infrastructure before launching. Most founders who choose this model are either well-capitalized or are physicians converting an existing multi-provider practice to a telehealth delivery model.

Franchise and Licensing Models

The franchise and licensing model is not an entry strategy — it is an exit or expansion strategy for an established operator with proven unit economics, documented protocols, and a technology platform robust enough to be white-labeled. In this model, the franchisor licenses the brand, clinical protocols, technology, pharmacy partnerships, and operational playbook to clinicians who operate under their own PCs. The franchisor earns royalties and technology licensing fees.

This model requires franchise legal counsel, an FDD (Franchise Disclosure Document) if the arrangement meets FTC franchise thresholds, robust compliance and oversight infrastructure, and a proven track record. Founders should not pursue a franchise model until they have 18–24 months of operating history and unit economics that are verifiably reproducible.

Legal Structure: MSO/PC and CPOM Laws

The legal structure of a TRT or HRT telehealth practice is not a formality — it is the foundation on which everything else rests, and getting it wrong creates regulatory exposure that can force expensive restructuring or trigger enforcement action from state medical boards.

The corporate practice of medicine (CPOM) doctrine is active in the majority of U.S. states and prohibits non-physicians from owning or controlling a medical practice. California, New York, Texas, New Jersey, and approximately 30 other states have enforceable CPOM rules. In these states, the clinical entity — the PC or PLLC — must be owned by a licensed physician. This restriction does not mean non-physicians cannot participate in the economics of the business; it means the structure must be carefully designed to separate clinical ownership from business operations.

The MSO/PC Structure Explained

The Management Services Organization (MSO) paired with a Professional Corporation (PC) is the industry-standard structure for telehealth practices with non-physician investors, co-founders, or scaling ambitions. The structure works as follows:

• The PC is a physician-owned entity that holds the medical practice, employs or contracts with all clinical staff, and is the entity that sees patients, generates prescriptions, and holds clinical licenses. It is owned 100% by a licensed physician in CPOM states.
• The MSO is a separate business entity (often structured as an LLC) that provides management, administrative, technology, marketing, and operational services to the PC under a Management Services Agreement (MSA). The MSO can be owned by anyone — physicians, non-physician founders, investors, or a combination.
• The MSA is the contract between the MSO and PC that defines services rendered, compensation (typically a management fee that captures a substantial portion of clinical revenues), and the operational relationship. The MSA must be structured to preserve genuine clinical independence of the PC while allowing the MSO to capture economic value. This document requires careful legal drafting — an MSA that appears to give the MSO control over clinical decisions is a CPOM violation regardless of the formal ownership structure.

For a solo physician launching a solo DTC practice with no investors and no non-physician co-founders, a simple PC or PLLC without an MSO is often sufficient for the first one to two years. If you anticipate bringing in investors, a non-physician business partner, or operating across multiple states with different CPOM rules, establish the MSO/PC structure from the beginning rather than restructuring later under time pressure.

Licensing and Credentialing

IMLC and State-by-State Licensing

Telehealth physicians must hold a medical license in every state where a patient is physically located at the time of the consultation. This requirement is absolute — prescribing to an unlicensed-state patient is practicing medicine without a license and creates criminal exposure in addition to civil liability. For a solo physician, limiting initial operations to one or two states is a practical approach to managing licensing timelines and costs. Expanding state-by-state as licensing is obtained is the standard growth path.

The Interstate Medical Licensure Compact (IMLC) dramatically accelerates multi-state licensing for eligible physicians. Physicians who qualify for IMLC — active license in good standing in a participating state, no disciplinary history, board certification — can apply for licenses in multiple IMLC member states simultaneously through a single application. IMLC currently includes 40+ states and processes applications in 30–60 days versus the 3–6 months typical for individual state applications. If you plan to operate in more than two states, IMLC enrollment should be your first licensing action.

Nurse practitioners and physician assistants have their own multi-state pathways through the Nurse Licensure Compact (NLC) for NPs and PA Licensure Compacts for PAs. Verify which compact your mid-level providers qualify for and in which states they hold active licenses before defining your patient geography.

DEA Registration for Testosterone

Testosterone in all injectable and implantable forms — testosterone cypionate, testosterone enanthate, testosterone propionate, and testosterone pellets — is classified as a Schedule III controlled substance under the Controlled Substances Act. Every prescriber at your clinic must hold an active DEA Controlled Substance Registration (CRS) at a registered address. The registration fee is $888 for practitioners and the application is submitted through the DEA Diversion Control Division online portal. Processing time averages 30–45 calendar days. Submit on the first day of your launch preparation — this timeline cannot be compressed.

The Ryan Haight Online Pharmacy Consumer Protection Act (2008) imposed an in-person evaluation requirement before prescribing any Schedule III controlled substance via telemedicine. The landscape has evolved significantly: DEA telemedicine rules were updated during the COVID-19 public health emergency and new permanent rules are under active rulemaking as of 2026. Some state telehealth frameworks and qualifying condition categories may permit remote-first prescribing; others require at least one in-person encounter. The rules are genuinely complex and active enforcement makes compliance non-negotiable. Obtain a written opinion from DEA-specialist healthcare counsel that explicitly addresses your target states and prescribing workflow before seeing your first patient. For a structured 90-day execution timeline that maps DEA registration in parallel with technology setup and pharmacy contracting, see the TRT clinic 90-day launch playbook.

Note that estradiol, progesterone, DHEA, and thyroid medications prescribed in women's HRT protocols are not controlled substances and do not require DEA registration. However, if your women's HRT protocol includes testosterone (commonly prescribed off-label for libido and energy in women), the DEA registration requirement applies equally.

Compounding Pharmacy Partnerships

Compounding pharmacy relationships are the fulfillment backbone of a TRT or HRT telehealth practice. FDA-approved commercial testosterone products (Androgel, Testim, Depo-Testosterone, Aveed) are available through standard retail pharmacies, but most telehealth TRT clinics rely on compounded formulations — particularly testosterone cypionate in oil for injection — because they offer cost advantages, dosing flexibility, and direct-to-patient shipping capabilities that commercial products do not. For women's HRT, bioidentical compounded estradiol, progesterone, and testosterone are standard protocols for most telehealth practices.

503A vs. 503B: Choosing the Right Pharmacy Category

Establish a minimum of two pharmacy partnerships from day one. Single-pharmacy dependency is the most common operational risk that kills TRT practice revenue continuity. FDA warning letters to compounding pharmacies — which have targeted multiple major TRT pharmacy partners in recent years — can halt patient fulfillment for weeks or months. Geographic redundancy also matters: some states have restrictions on which out-of-state compounding pharmacies can ship to patients within their borders, and a backup pharmacy in a different jurisdiction provides continuity when shipping restrictions affect your primary partner.

Clinical Protocol Development

Written clinical protocols are both your standard-of-care documentation and your operational standardization mechanism. A TRT or HRT practice without written protocols signed by the medical director is operating without the most basic safety and compliance infrastructure. Protocols must be developed before the first patient is seen, reviewed by a healthcare attorney familiar with state medical board standards, versioned and dated, and updated at least annually. As your patient base matures, many TRT patients will inquire about adding a GLP-1 agent — the GLP-1 + TRT combination therapy management guide covers dual-protocol titration scheduling, expanded lab panels, and subscription bundling for combination patients.

TRT Dosing and Monitoring Protocols

A complete men's TRT protocol stack covers six clinical pathways. Each must be documented in sufficient detail that any credentialed provider at your practice can implement the protocol consistently without real-time physician oversight for routine cases.

Initial Evaluation Protocol

Define the required baseline laboratory panel (total testosterone, free testosterone, LH, FSH, SHBG, estradiol, PSA for men over 40, CBC with hematocrit, CMP, lipid panel), the diagnostic threshold for hypogonadism, contraindications to TRT (active prostate cancer, polycythemia, severe sleep apnea without CPAP, desire for fertility in the near term), and the required clinical history elements that must be documented before any prescription is generated.

Starting Dose Protocol

Specify the initial testosterone cypionate dose range (typically 100–160 mg per week IM or 50–80 mg twice weekly for subcutaneous), formulation options (injection, topical gel, pellet), injection site guidance (ventrogluteal, dorsogluteal, deltoid, or subcutaneous options), and the informed consent elements that must be documented before treatment begins. Include anastrozole initiation criteria — most protocols initiate estrogen management only when estradiol exceeds a defined threshold (commonly 40–50 pg/mL) rather than prophylactically.

Follow-Up and Titration Protocol

Define the required follow-up lab timeline (week 6–8 after initiation, week 12, then semi-annual for stable patients), the target total testosterone range for therapeutic optimization (typically 600–1,000 ng/dL), and the dose adjustment algorithm based on lab results and symptom response. Include upper limits that trigger dose reduction and hematocrit thresholds that require temporary cessation or therapeutic phlebotomy. Automating this lab schedule through your EHR platform is critical at scale — see testosterone lab tracking software for a detailed breakdown of automated ordering, LOINC-coded biomarker thresholds, and alert configuration.

Ancillary and Off-Cycle Protocol

Document the protocol for HCG or enclomiphene use in patients who want to preserve fertility or testicular function. Specify the enclomiphene dosing range (12.5–25 mg daily), monitoring parameters, and criteria for transitioning between TRT and fertility-preserving protocols. This pathway is increasingly requested by men under 40 who are testosterone-deficient but not yet ready for indefinite suppression of endogenous production.

Women's HRT Regimens

Women's HRT protocols require a distinct clinical framework. The patient population spans perimenopausal women in their late 30s to post-menopausal women in their 60s and 70s, with dramatically different clinical presentations and treatment goals.

Baseline Evaluation

Required baseline labs for women's HRT include: estradiol, progesterone (day 21 for cycling women), total and free testosterone, DHEA-S, TSH, free T3, free T4, FSH, LH, CBC, CMP, and lipid panel. Document contraindications clearly: estrogen-sensitive cancers (breast, endometrial), active thromboembolism, unexplained vaginal bleeding, and uncontrolled hypertension are absolute contraindications in most protocols.

Estradiol and Progesterone Regimens

Specify the available estradiol delivery routes (transdermal patch, topical gel or cream, vaginal, oral — noting that oral estradiol has higher first-pass thrombotic risk), starting doses for each, and titration intervals. For women with an intact uterus, document the mandatory concurrent progesterone protocol (micronized progesterone is preferred for bioidentical HRT programs) and the rationale for its inclusion in all communications.

Testosterone for Women

Off-label testosterone for women (prescribed for libido, energy, mood, and cognitive function) is a growing component of comprehensive HRT practices. Compounded testosterone in low-dose formulations (typically 1–5 mg daily transdermal) is the standard delivery method. Document starting dose, monitoring intervals (total and free testosterone, SHBG, estradiol at 8 weeks), and the virilization monitoring protocol including androgenic side effects that indicate dose reduction.

Technology Platform Selection

The technology platform decision is the highest-leverage choice in your first 60 days. A wrong decision here costs far more than the switching cost to correct it: clinical data migration, provider retraining, new BAA negotiations, and rebuilding patient workflows are six-figure problems for a practice with 200+ active patients. Make this decision deliberately, evaluate multiple options, and prioritize platform fit over cost. For a structured comparison of available HRT clinic platforms, see the HRT clinic software comparison.

The critical evaluation criteria for TRT/HRT platform selection, in priority order, are: (1) Native EPCS for Schedule III controlled substances — this is non-negotiable and cannot be effectively retrofitted; (2) Lab integration with LabCorp, Quest, or specialty labs with automated result routing and out-of-range flagging; (3) Subscription billing with pause, resume, failed payment dunning, and refund workflow; (4) Asynchronous telehealth capability for lab review visits and follow-up touchpoints that do not require synchronous video; and (5) Protocol enforcement built into the provider workflow to maintain clinical consistency across multiple providers.

Patient Acquisition Strategy

Patient acquisition for a TRT or HRT telehealth practice combines three channels that operate on different timelines: SEO content (6–18 months to meaningful organic traffic), paid digital advertising (immediate results, ongoing cost), and referral programs (high quality patients, slow to build). A well-designed practice activates all three from day one and relies on paid acquisition to fund operations while organic and referral channels develop. Capturing and converting leads efficiently requires a structured hormone clinic patient onboarding process — intake form design and abandonment rates directly determine how much of your marketing spend actually converts to active patients.

SEO and Content Marketing

TRT and HRT are high-commercial-intent search categories with significant search volume and relatively high cost-per-click in paid channels ($15–$45 for top-tier keywords). A content strategy that targets long-tail informational queries — "TRT protocol for beginners," "HRT options for perimenopause," "low testosterone symptoms in men over 40," "compounded testosterone vs commercial" — builds organic traffic that converts at higher rates than paid because visitors arrive already educated about treatment options.

Geographic SEO is particularly valuable for practices targeting specific metro areas. Queries like "TRT clinic [city]" and "online HRT prescription [state]" have high commercial intent and moderate competition outside major metros. Building location-specific landing pages and content for your target states accelerates local organic rankings.

Paid Digital Advertising

Google Search and Meta (Facebook/Instagram) are the two primary paid channels for TRT/HRT patient acquisition. Google Search captures patients actively searching for treatment; Meta captures patients in the awareness phase who may not yet know they have a treatable condition. Both channels require attention to advertising policy restrictions: Google and Meta prohibit certain health claims, before-and-after testimonials, and targeting based on inferred health conditions. Work with a digital marketing agency experienced in telehealth advertising compliance to avoid account bans that can shut down your primary acquisition channel.

Expect a cost per acquired patient of $120–$280 for TRT and $180–$350 for women's HRT at launch, improving to $80–$180 and $130–$250 respectively as campaigns are optimized. At a $200/month average revenue per patient and 3–5% monthly churn, the lifetime value of a TRT patient is $4,000–$6,700 — well above acquisition costs at any reasonable efficiency level.

Referral and Professional Networks

Referral programs targeting existing patients (offer one free month for a referred friend who enrolls) consistently deliver the lowest-cost, highest-quality patients in TRT and HRT practices. Patients who are referred by existing members have 40–60% lower churn rates in the first 90 days than patients acquired through paid channels. Build the referral mechanism into your technology platform's patient portal and activate it at the 60-day mark when your earliest patients have experienced enough of the clinical benefit to advocate authentically.

Professional referrals from primary care physicians, OB-GYNs, urologists, and functional medicine practitioners are a slower-building but high-quality channel. Developing relationships with PCPs in your target geographies — through educational content, co-marketing, and case consultation offers — builds a referral pipeline that is highly durable once established.

Pricing and Revenue Model Design

TRT and HRT telehealth practices primarily operate on membership subscription models because the clinical reality of hormone therapy aligns perfectly with recurring revenue: treatment is ongoing, monitoring is regular, and patients who are on therapy have a high incentive to maintain their subscription. Fee-for-service pricing is rarely used for active treatment phases, though it may appear at initial consultation. For a detailed breakdown of how to structure subscription tiers and maximize patient lifetime value, see the guide to TRT pricing strategy and patient lifetime value.

Pricing Tiers

Most successful practices use a two or three-tier membership structure. A representative structure:

Pharmacy cost pass-through (compounded testosterone, anastrozole, HCG) is typically handled separately from the membership fee — either billed to the patient directly by the pharmacy or invoiced by the practice at cost-plus. This separation keeps the membership price stable and predictable while pharmacy cost fluctuations are passed through rather than absorbed. Clearly disclose the pharmacy cost structure in your informed consent and membership agreement. For a full financial modeling comparison of subscription versus per-visit billing at different patient scales, see the TRT subscription billing model analysis.

Pricing psychology matters: launch at your sustainable long-term price, not a discounted launch price. Discounts attract price-sensitive patients who churn first and complain most. The most durable TRT and HRT practices compete on clinical quality, convenience, and patient experience — not price. Setting a price that reflects clinical value from day one attracts patients who make retention-friendly decisions.

Staffing Plan

TRT and HRT practices have a predictable staffing trajectory driven by active patient count. The milestones below are benchmarks based on operational data from telehealth hormone practices; specific numbers will vary by workflow automation maturity and service complexity.

Patient coordinators are the highest-leverage hire for retention. In TRT and HRT practices, coordinators handle onboarding calls, lab result communication, refill coordination, and patient questions that do not require a clinical consultation. A single skilled coordinator managing inbound patient communication reduces churn by 30–50% compared to practices that rely entirely on asynchronous messaging. Hire your first dedicated coordinator at 80–100 active patients, before patient communication volume becomes a bottleneck.

Compliance Framework

A TRT or HRT telehealth practice operates under at least five distinct regulatory frameworks simultaneously. Treating compliance as a post-launch checklist creates the conditions for an enforcement action that can suspend operations. Build compliance infrastructure before launch, not after. Practices operating across multiple states face additional complexity around controlled substance prescribing — the multi-state TRT prescribing compliance guide covers state-by-state DEA registration requirements, PDMP obligations, and telehealth prescribing rules in detail.

Financial Projections

Startup Budget

Year 1–3 Revenue Projections

The projections below model a dual-population practice (men's TRT and women's HRT) with an average revenue per patient of $215/month, a patient acquisition cost of $200, and a monthly churn rate of 4%. Marketing spend is consistent at $4,000–$6,000/month through year two.

Scaling Roadmap

The scaling path for a TRT/HRT telehealth practice has four identifiable stages, each with distinct operational priorities. Understanding which stage you are in prevents premature scaling (investing in multi-provider infrastructure before patient volume justifies it) and delayed scaling (missing the window to add capacity before patient wait times damage conversion and retention).

Stage 1: Solo Launch (0–150 Patients)

The founding physician or primary NP handles all clinical work. The founder handles all administrative work. Priorities are: getting to 50 active patients as fast as possible to validate the acquisition model, optimizing intake and onboarding to minimize time-per-patient while maintaining clinical quality, and building the protocol and technology foundation that will support the next stage. Do not hire prematurely — headcount before revenue is the fastest way to extend the path to break-even.

Stage 2: First Team (150–400 Patients)

Add a patient coordinator at 80–100 patients. Add the first NP or PA when your panel consistently has a two-week wait for new patients or when you miss consultations because your calendar is full. At this stage, standardize protocols in your EHR, document every operational workflow, and build the training materials that will allow the next hire to reach productivity in two weeks rather than eight.

Stage 3: Multi-Provider Growth (400–1,000 Patients)

Operating at 400+ patients requires formal management infrastructure: a clinical manager or lead NP to own protocol compliance, a patient success team of 2–3 coordinators, and a defined QA process including monthly chart audits. This is the stage where data becomes essential — patient acquisition cost trends, churn cohort analysis, provider productivity metrics, and referral source tracking should be reviewed monthly.

Stage 4: Multi-State or Multi-Location (1,000+ Patients)

At 1,000+ patients, the MSO/PC structure is fully operational, multi-state licensing is established across all target states, and the practice has the data to evaluate which patient acquisition channels and geographic markets to invest in next. Consider adding adjacent protocol categories — peptide therapy, metabolic health, sexual health — to increase average revenue per patient without proportional acquisition cost increases. Geographic expansion to new states should follow IMLC enrollment, not precede it. For a detailed operational roadmap of the full multi-location journey, see scaling a TRT practice from solo provider to multi-location.

Common Mistakes